Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18-47.

Article  PubMed  PubMed Central  Google Scholar 

Paterniti MO, Bi Y, Rekić D, Wang Y, Karimi-Shah BA, Chowdhury BA. Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2017;14:1395–402.

Article  PubMed  Google Scholar 

Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020;55:2000085.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nasser M, Larrieu S, Si-Mohamed S, Ahmad K, Boussel L, Brevet M, et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J. 2021;57:2002718.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pugashetti J, Graham J, Boctor N, Mendez C, Foster E, Juarez M, et al. Weight loss as a predictor of mortality in patients with interstitial lung disease. Eur Respir J. 2018;52:1801289.

Article  PubMed  PubMed Central  Google Scholar 

Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518–28.

Article  CAS  PubMed  Google Scholar 

Comes A, Wong AW, Fisher JH, Morisset J, Johannson KA, Farrand E, et al. Association of BMI and change in weight with mortality in patients with fibrotic interstitial lung disease. Chest. 2022;161:1320–9.

Article  PubMed  Google Scholar 

Alakhras M, Decker PA, Nadrous HF, Collazo-Clavell M, Ryu JH. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest. 2007;131:1448–53.

Article  PubMed  Google Scholar 

Kishaba T, Nagano H, Nei Y, Yamashiro S. Body mass index—percent forced vital capacity—respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients. J Thorac Dis. 2016;8:3596–604.

Article  PubMed  PubMed Central  Google Scholar 

Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Valenzuela C, et al. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res. 2020;21:312.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Awano N, Jo T, Yasunaga H, Inomata M, Kuse N, Tone M, et al. Body mass index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis. ERJ Open Res. 2021;7:00037–2021.

Article  PubMed  PubMed Central  Google Scholar 

Jouneau S, Rousseau C, Lederlin M, Lescoat A, Kerjouan M, Chauvin P, et al. Malnutrition and decreased food intake at diagnosis are associated with hospitalization and mortality of idiopathic pulmonary fibrosis patients. Clin Nutr. 2022;41:1335–42.

Article  CAS  PubMed  Google Scholar 

Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Yang M, et al. Post hoc analysis of clinical outcomes in placebo- and pirfenidone-treated patients with IPF stratified by BMI and weight loss. Respiration. 2022;101:142–54.

Article  CAS  PubMed  Google Scholar 

Nagy A, Palmer E, Polivka L, Eszes N, Vincze K, Barczi E, et al. Treatment and systemic sclerosis interstitial lung disease outcome: the overweight paradox. Biomedicines. 2022;10:434.

Article  PubMed  PubMed Central  Google Scholar 

Doubková M, Švancara J, Svoboda M, Šterclová M, Bartoš V, Plačková M, et al. EMPIRE Registry, Czech part: impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin Respir J. 2018;12:1526–35.

Article  PubMed  Google Scholar 

Snyder L, Neely ML, Hellkamp AS, O’Brien E, de Andrade J, Conoscenti CS, et al. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019;20:105.

Article  PubMed  PubMed Central  Google Scholar 

Brown KK, Inoue Y, Flaherty KR, Martinez FJ, Cottin V, Bonella F, et al. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology. 2022;27:294–300.

Article  PubMed  PubMed Central  Google Scholar 

Nakatsuka Y, Handa T, Kokosi M, Tanizawa K, Puglisi S, Jacob J, et al. The clinical significance of body weight loss in idiopathic pulmonary fibrosis patients. Respiration. 2018;96:338–47.

Article  PubMed  Google Scholar 

Kulkarni T, Yuan K, Tran-Nguyen TK, Kim YI, de Andrade JA, Luckhardt T, et al. Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients. PLoS ONE. 2019;14: e0221905.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalininskiy A, Rackow AR, Nagel D, Croft D, McGrane-Minton H, Kottmann RM. Association between weight loss and mortality in idiopathic pulmonary fibrosis. Respir Res. 2022;23:377.

Article  PubMed  PubMed Central  Google Scholar 

Kim TH, Shin YY, Kim HJ, Song MJ, Kim YW, Lim SY, et al. Impact of body weight change on clinical outcomes in patients with idiopathic pulmonary fibrosis receiving pirfenidone. Sci Rep. 2022;12:17397.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sekine A, Wasamoto S, Hagiwara E, Yamakawa H, Ikeda S, Okabayashi H, et al. Beneficial impact of weight loss on respiratory function in interstitial lung disease patients with obesity. Respir Investig. 2021;59:247–51.

Article  PubMed  Google Scholar 

Schaeffer MR, Kumar DS, Assayag D, Fisher JH, Johannson KA, Khalil N, et al. Association of BMI with pulmonary function, functional capacity, symptoms, and quality of life in ILD. Respir Med. 2022;195: 106792.

Article  PubMed  Google Scholar 

Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718–27.

Article  CAS  PubMed  Google Scholar 

Flaherty KR, Wells AU, Cottin V, Devaraj A, Inoue Y, Richeldi L, et al. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J. 2022;59:2004538.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cottin V, Martinez FJ, Jenkins RG, Belperio JA, Kitamura H, Molina-Molina M, et al. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial. Respir Res. 2022;23:85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine–reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189–94.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency. Guideline on the investigation of subgroups in confirmatory clinical trials. 2019. EMA/CHMP/539146/2013. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-subgroups-confirmatory-clinical-trials_en.pdf.

Garcia-Hernandez A, Rizopoulos D. %JM: a SAS macro to fit jointly generalized mixed models for longitudinal data and time-to-event responses. J Stat Softw. 2018;84:29.

Article  Google Scholar 

Jouneau S, Lescoat A, Crestani B, Riemekasten G, Kondoh Y, Smith V et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) by body mass index (BMI) at baseline: subgroup analysis of the SENSCIS trial. Poster presented at the American Thoracic Society International Conference. 2020. https://www.usscicomms.com/respiratory/ATS2020/jouneau.

Moon SW, Choi JS, Lee SH, Jung KS, Jung JY, Kang YA, et al. Thoracic skeletal muscle quantification: low muscle mass is related with worse prognosis in idiopathic pulmonary fibrosis patients. Respir Res. 2019;20:35.

Article  PubMed  PubMed Central  Google Scholar 

Nakano A, Ohkubo H, Taniguchi H, Kondoh Y, Matsuda T, Yagi M, et al. Early decrease in erector spinae muscle area and future risk of mortality in idiopathic pulmonary fibrosis. Sci Rep. 2020;10:2312.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med. 1988;167:1211–27.

Article  CAS  PubMed  Google Scholar 

Arisido MW, Antolini L, Bernasconi DP, Valsecchi MG, Rebora P. Joint model robustness compared with the time-varying covariate Cox model to evaluate the association between a longitudinal marker and a time-to-event endpoint. BMC Med Res Methodol. 2019;19:222.

Article  PubMed  PubMed Central  Google Scholar 

Papageorgiou G, Mauff K, Tomer A, Rizopoulos D. An overview of joint modeling of time-to-event and longitudinal outcomes. Annu Rev Stat Appl. 2019;6:223–40.

Article  Google Scholar 

Arbeeva L, Nelson AE, Alvarez C, Cleveland RJ, Allen KD, Golightly YM, et al. Application of traditional and emerging methods for the joint analysis of repeated measurements with time-to-event outcomes in rheumatology. Arthritis Care Res (Hoboken). 2020;72:615–21.

Article  PubMed  PubMed Central  Google Scholar 

Chen Y, Postmus D, Cowie MR, Woehrle H, Wegscheider K, Simonds AK, et al. Using joint modelling to assess the association between a time-varying biomarker and a survival outcome: an illustrative example in respiratory medicine. Eur Respir J. 2021;57:2003206.